Abstract
Background and importanceNewly formulated Thiotepa Riemser was approved in 2021 for conditioning treatment before allogeneic or autologous haematopoietic progenitor cell transplantation.Prior to administration Thiotepa Riemser is reconstituted with water for...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Hospital Pharmacy: Science and Practice
Paper Title
Journal
Date
